Positives

• In mice, SLU-PP-332 boosted exercise endurance and oxidative type IIa muscle fibers without exercise, an attractive concept for PEM-limited LC patients PMC.
  
  
• Preclinical models showed increased energy expenditure, fat oxidation and reversal of metabolic syndrome features PMC.
  
  

Negatives

• All evidence is rodent or in vitro; no patient has used SLU-PP-332 in a controlled setting, so efficacy and safety in humans are unknown bioRxiv.
  
  
• Off-target ERRbeta/gamma activation could affect cardiac and CNS tissue, with unclear long-term consequences ACS Chemical Biology.
  
  

Hurdles & Side Effects

• As of April 2026, no human trial of SLU-PP-332 is registered on ClinicalTrials.gov Frontiers in Physiology.
  
  
• The compound is sold only as research-grade material with no purity or dosing standards for patient use PMC.